Global Rank End-point: The PANORAMA-HF trial [9] assessed ARNI versus enalapril in pediatric LV systolic dysfunction, introducing a global rank endpoint that combines clinical events, including a decrease in beta-natriurteic peptide (BNP) levels, improvement in NYHA/Ross classifications, and patient-reported symptoms. Here, NPPB is linked to hydrops fetalis.